(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 October 2009 (29.10.2009)

PCT

(10) International Publication Number
WO 2009/130261 A1

(51) **International Patent Classification**:
*A61K 39/12* (2006.01) *A61K 39/39* (2006.01)
*C07K 14/18* (2006.01) *A61K 47/48* (2006.01)
*C12N 7/04* (2006.01)

(21) **International Application Number**:
PCT/EP2009/054856

(22) **International Filing Date**:
22 April 2009 (22.04.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
08154974.3 22 April 2008 (22.04.2008) EP

(71) **Applicant** *(for all designated States except US)*: **CYTOS BIOTECHNOLOGY AG** [CH/CH]; Wagistrasse 25, CH-8952 Schlieren (CH).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **BACHMANN, Martin** [CH/CH]; Goldackerweg 8, CH-8472 Seuzach (CH). **HUBER, Adrian** [CH/CH]; Eschergutweg 5, CH-8049 Zürich (CH). **IVANOVA, Lidia** [US/CH]; Schulstrasse 31, CH-8952 Schlieren (CH).

(74) **Agent**: **KRISHNAN, Sri**; Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

**Published**:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2009/130261 A1

(54) **Title**: VACCINE COMPOSITIONS FOR THE TREATMENT OF DENGUE FEVER AND USES THEREOF

(57) **Abstract**: The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and / or prevention of dengue fever. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is a dengue antigen. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against dengue virus, preferably against dengue virus of any one of serotypes 1 to 4. Thus, the invention further provides methods of treating, ameliorating and/or preventing dengue virus infection by way of active immunization against domain III of the dengue virus envelope protein E, or against antigenic fragments thereof.